CDKN1A and chronic kidney disease: VDAs inhibited cell proliferation in 3 out of 4 lines. The effect was dose-dependent and correlated with increased levels of CKD inhibitors, p21 and p27. Tumor inhibition was accompanied by in vivo upregulation of p21 and p27 expression.